Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,422 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro | completed | — | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00963820 | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02220608 | Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT01270932 | Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT00461045 | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | CelgeneINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT00349778 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | completed | Phase 2 | 102 | Stanford UniversityOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01057225 | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Mayo ClinicOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00686556 | Total Marrow Irradiation for Refractory Acute Leukemia | completed | Phase 1 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00602693 | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | completed | Phase 1 | 41 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02103335 | Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 2 | Nov 22, 2017 | clinicaltrials |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | completed | Phase 3 | 97 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00577512 | 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | completed | Phase 2 | 4 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 6 | Nov 20, 2017 | clinicaltrials |
| NCT00701844 | Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | completed | N/A | 315 | University of North Carolina, Chapel HillOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT02252263 | A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma | completed | Phase 1 | 44 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2017 | clinicaltrials |
| NCT02046915 | Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide(PERSPECTIVE) | completed | Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00871910 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | completed | Phase 1 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 23, 2017 | clinicaltrials |
| NCT01764880 | SST0001 (Roneparstat) in Advanced Multiple Myeloma | completed | Phase 1 | 19 | Sigma Tau Research Switzerland SAINDUSTRY | 3 | Oct 23, 2017 | clinicaltrials |
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00899847 | Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00056160 | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 353 | CelgeneINDUSTRY | 2 | Oct 19, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01660750 | A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma(11-MM-01) | completed | Phase 1 | 29 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00081939 | UARK 2003-33, Total Therapy III | completed | Phase 2 | 303 | University of ArkansasOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT00054353 | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 16, 2017 | clinicaltrials |
| NCT02885038 | Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies(TCP) | completed | — | 1,101 | Etablissement Français du SangOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01495351 | Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma | completed | Phase 1 | 19 | AHS Cancer Control AlbertaOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01593410 | Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 194 | CelgeneINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01689987 | Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 18 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00410605 | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2017 | clinicaltrials |
| NCT00511238 | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 312 | AmgenINDUSTRY | 2 | Aug 31, 2017 | clinicaltrials |
| NCT00670631 | Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | completed | Phase 2 | 46 | Guido TricotOTHER | 0 | Aug 31, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02655458 | Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | completed | Phase 1 | 15 | Hearn Jay ChoOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01393964 | Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT01339572 | Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | completed | Phase 2 | 72 | University of FloridaOTHER | 1 | Aug 1, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jan 19, 2018source: clinicaltrials